Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NERV | US
-0.09
-3.37%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.58
2.59
2.68
2.58
Minerva Neurosciences Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia currently submitted an New Drug Application (NDA); and MIN-301 a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop sell and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals Inc. and changed its name to Minerva Neurosciences Inc. in 2013. Minerva Neurosciences Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.6%1 month
28.6%3 months
42.7%6 months
52.5%-
11.21
2.68
-1.95
1.87
2.60
0.03
-
-26.21M
18.04M
18.04M
-
-
-
-
-675.09
0.93
0.24
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.21
Range1M
0.42
Range3M
0.88
Rel. volume
0.52
Price X volume
15.35K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 16.3 | 19.27M | 6.19% | n/a | 0.22% |
Sol-Gel Technologies Ltd | SLGL | Biotechnology | 0.678 | 18.89M | 1.19% | n/a | 3.99% |
Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.4456 | 17.88M | -0.49% | n/a | 2.71% |
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 2.35 | 17.54M | 21.13% | n/a | 3.49% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5269 | 17.54M | 58.04% | n/a | 6.82% |
Athira Pharma Inc | ATHA | Biotechnology | 0.4477 | 17.21M | -1.52% | n/a | 1.69% |
GeoVax Labs Inc | GOVX | Biotechnology | 2.01 | 17.15M | -4.29% | n/a | -6.03% |
ICU | ICU | Biotechnology | 4.02 | 16.85M | -4.29% | n/a | -45.50% |
IN8bio Inc. Common Stock | INAB | Biotechnology | 0.2301 | 16.69M | 0.52% | n/a | 43.30% |
Synlogic Inc | SYBX | Biotechnology | 1.42 | 16.61M | -1.39% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.60 | 0.53 | Expensive |
Ent. to Revenue | 0.03 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 2.68 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 42.73 | 72.92 | Lower Risk |
Debt to Equity | -1.95 | -1.24 | Cheaper |
Debt to Assets | 1.87 | 0.25 | Expensive |
Market Cap | 18.04M | 3.78B | Emerging |